Genentech: Kelly Storek | Principal Scientist, Infectious Diseases and Host-Microbe Interactions, Research Biology

Scientists / Our Scientists

"Microbes are intricately interconnected to human biology. It is a privilege to detangle these interactions and use microbes as next generation therapies to improve patients’ lives."

Years at Genentech

Publications at Genentech

Awards & Honors

Since my first undergraduate class looking at dirt under the microscope, I have been fascinated by bacteria. My career has focused on studying and manipulating bacteria alone and in communities, as well as interrogating how they influence inflammation and disease pathways in humans.

My training has spanned studying the virulence factors in aquatic fish pathogens to biofilm formation by Pseudomonas aeruginosa to human intracellular bacterial infections. After completing my postdoctoral fellowship at Stanford University, I joined Genentech’s Infectious Disease Department in 2015 as a Principal Scientific Researcher discovering novel antibacterial compounds targeting Gram-negative bacterial pathogens. In 2020, I transitioned to a Senior Scientist and now lead a group centered on studying and engineering microbes to treat diseases.

Featured Publication

Monoclonal antibody targeting the β-barrel assembly machine of Escherichia coli is bactericidal.

Proc Natl Acad Sci.115(14):3692

Storek KM, Auerbach MR, Shi H, Garcia NK, Sun D, Nickerson NN, Vij R, Lin Z, Chiang N, Schneider K, Wecksler AT, Skippington E, Nakamura G, Seshasayee D, Koerber JT, Payandeh J, Smith PA and Rutherford ST. (2018)

View Abstract

My lab focuses on microbes within the human gut, which depending on the environment can be beneficial, detrimental, or somewhere in between. We aim to use clinical samples and data to uncover important bacterial pathways in disease, and discover drugs that appropriately influence these pathways to bring forward novel therapies for patients.

While microbes are typically thought of as pathogens, many species are important and essential to human health. Our group is working to identify beneficial bacterial species and genetically engineer them to deliver therapeutics. These next generation delivery vehicles have the potential to precisely deliver therapeutics to the GI tract for diseases such as IBD.

Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling

Proceedings of the National Academy of Sciences of the United States of America, ISSN: 00278424

Naruhisa Ota; Christopher W. Davies; Jing Kang; Donghong Yan; Alexis Scherl; Anne Wong; Ryan Cook; Xun Tao; Debra Dunlap; Sha Klabunde; Priscilla Mantik; Vishnu Mohanan; WeiYu Lin; Jacqueline McBride; Shraddha Sadekar; Kelly M. Storek; Patrick J. Lupardus; Zhengmao Ye; Heidi J. A. Wallweber; James R. Kiefer; Min Xu; Pamela Chan; Karthik Nagapudi; Tangsheng Yi; James T. Koerber

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Kelly Storek

Principal Scientist, Infectious Diseases and Host-Microbe Interactions, Research Biology

Featured Publication

Monoclonal antibody targeting the β-barrel assembly machine of Escherichia coli is bactericidal.